What Happens If You Stop Taking Sertraline?

Stopping sertraline abruptly can trigger a cluster of physical and psychological symptoms collectively known as antidepressant discontinuation syndrome. These range from dizziness and nausea to the strange electrical-shock sensations many people call “brain zaps.” Not everyone experiences withdrawal, and sertraline is actually milder than some of its close relatives in this regard, but the symptoms are real enough that clinicians and researchers have spent decades studying how to make the process smoother.

What Withdrawal Symptoms Feel Like

People who stop sertraline describe a wide and sometimes bewildering range of symptoms. In qualitative research where patients were interviewed about their experiences, every participant reported physical side effects during withdrawal. The list included tiredness, nausea, sleep disruptions such as nightmares and vivid dreams, night sweats, diarrhea, vomiting, sweating, ringing in the ears, headaches, dizziness, joint pain, and a feeling of restlessness so intense one person described it as feeling like “a wild animal stuck in barbed wire.”¹ Emotional symptoms are common too. Anxiety, irritability, and sudden mood swings often appear alongside the physical discomfort, making it genuinely difficult for people to tell whether their original depression is returning or whether these are temporary effects of stopping the drug.

A systematic review of withdrawal in children and adolescents noted a similar symptom profile: irritability, palpitations, anxiety, nausea, sweating, headaches, insomnia, abnormal skin sensations, and dizziness. The underlying mechanism involves shifts in serotonin transporter expression and receptor sensitivity that also spill over into dopamine and norepinephrine pathways.² In other words, your brain has adapted to having sertraline on board, and when the drug leaves, multiple neurotransmitter systems have to readjust at once.

Brain Zaps

Of all the withdrawal symptoms, “brain zaps” are the most distinctive and the hardest to explain to someone who hasn’t felt them. People describe them as brief electric-shock sensations in the head, sometimes radiating into the limbs, often triggered or worsened by moving the eyes side to side. A study focused specifically on this phenomenon found that the most common cause was abrupt discontinuation of an antidepressant. Gradual tapering helped somewhat, but only partially; many people still experienced the zaps even when weaning off slowly.³ An unexpected finding was a strong link between brain zaps and lateral eye movements, suggesting the two share a neurological pathway that researchers still do not fully understand.

Brain zaps are not dangerous, but they can be alarming if no one has warned you about them. They tend to diminish over days to weeks, though for some people they linger much longer. If you are tapering off sertraline and start noticing these sensations, knowing what they are can at least take the edge off the anxiety they provoke.

When Symptoms Peak and How Long They Last

Withdrawal symptoms typically do not appear the moment you skip a pill. Sertraline has a half-life of about 26 hours, so its levels drop meaningfully within a day or two after the last dose. Most people notice the first symptoms within two to four days. Research tracking symptom scores after discontinuation found that withdrawal symptoms peaked around day 22, on average, before beginning to ease.⁴ That three-week peak can feel like a long time when you’re in the middle of it, and for some individuals the symptoms stretch out over months, depending on how quickly the dose was reduced and how long they had been taking the drug.

An interesting wrinkle is that sertraline’s serotonin transporter occupancy appears to decrease more slowly than its blood plasma concentration. Researchers reviewing the relationship between dose and transporter occupancy noted this delayed decline for sertraline specifically, and speculated it may contribute to the somewhat delayed onset of withdrawal effects that clinicians observe.⁵ In practical terms, you might feel fine for the first few days after stopping and then get hit with symptoms later than expected.

Why How Long You’ve Been Taking It Matters

The single biggest risk factor for difficult withdrawal is how long you’ve been on the medication. This makes intuitive sense: the longer your brain has had serotonin levels propped up by sertraline, the more deeply it has adapted. A review of published data found a clear gradient between duration of antidepressant use and both the likelihood and severity of withdrawal symptoms, consistent with greater physiological adaptation over time.⁶

A more recent survey put numbers to this pattern. In fully adjusted models, people who had been taking antidepressants for more than 24 months before stopping were roughly ten times more likely to experience a withdrawal syndrome than those who had used the medication for fewer than six months. They were about five times more likely to report their withdrawal effects as severe, their symptoms lasted longer on average, and they were far less likely to be able to stop successfully.⁷ That last finding is worth lingering on: people who had taken the drug longest were nearly 28 times less likely to be able to stop at all. This doesn’t mean long-term users can never quit, but it does mean they typically need a much slower, more carefully managed taper.

How Sertraline Compares to Other SSRIs

If you scan online forums, you’ll find heated debates about which antidepressant is hardest to quit. The evidence gives a fairly consistent answer: paroxetine (Paxil) is the worst offender by a comfortable margin, and fluoxetine (Prozac) is the easiest. Sertraline falls somewhere in the middle. A post-marketing safety comparison of four SSRIs found that withdrawal reactions accounted for about 5% of all reports for paroxetine, compared with less than 1% for sertraline. When measured per thousand prescriptions, paroxetine generated ten times more withdrawal reports than sertraline.⁸

Fluoxetine’s advantage comes from its unusually long half-life. Its active metabolite stays in the body for days to weeks, which essentially creates a natural, built-in taper. Sertraline lacks that cushion. Its half-life is about a day, meaning levels drop fairly quickly after the last dose. That said, sertraline’s occupancy at the serotonin transporter may linger a bit longer than its plasma levels suggest, as noted earlier, which could partially buffer the transition compared to paroxetine, whose transporter occupancy drops more in lockstep with blood levels.⁹

Telling Withdrawal Apart from Relapse

This is one of the most practically important questions people face when stopping sertraline, and one of the trickiest. Withdrawal symptoms and a genuine return of depression can look strikingly similar: low mood, anxiety, irritability, sleep disruption, fatigue. Confusing the two can lead to the wrong decision. If you mistake withdrawal for relapse, you might restart the medication unnecessarily. If you mistake relapse for withdrawal, you might tough it out when you actually need treatment.

Timing offers the best clue. Research tracking both withdrawal scores and depression scores after discontinuation found that withdrawal symptoms peaked earlier than depressive symptoms. Withdrawal scores hit their maximum around day 22, while depression scores peaked around day 28.⁴ That roughly one-week gap provides a useful rule of thumb: symptoms that arrive within the first few weeks and then begin improving are more likely withdrawal, while symptoms that build gradually over a month or longer may signal relapse. Physical symptoms like dizziness, brain zaps, and nausea are also strong markers of withdrawal specifically, since they aren’t typical features of depression itself.

How to Taper Safely

The simplest and most important advice is: don’t stop cold turkey. The goal of tapering is to reduce the dose gradually enough that your brain can readjust without provoking a severe withdrawal response. For people at low risk, guidelines suggest reducing the dose by roughly 25 to 50% at a time over two to six weeks. A typical schedule for someone on 100 mg of sertraline might be to drop to 50 mg, then 25 mg, then stop, with each step lasting about two weeks.¹⁰

That standard approach works for many people, but a meaningful subset finds it too fast. If you’ve been on sertraline for a long time, if you’re on a high dose, or if you’ve struggled with previous attempts to stop, a slower taper with smaller reductions may be necessary. In some cases this means tapering all the way down to very low doses, as low as 1 mg, before finally stopping. Getting to those tiny doses often requires a liquid formulation of the drug or a specially compounded preparation, since standard tablets can’t easily be split that small.¹¹

When Standard Tapering Isn’t Enough

The concept behind very gradual, or “hyperbolic,” tapering comes from the way sertraline and similar drugs interact with the serotonin transporter. The relationship between dose and transporter occupancy isn’t a straight line; it’s a curve. At higher doses, a given reduction barely changes how much of the transporter is occupied. But at lower doses, the same milligram reduction creates a much larger shift in transporter occupancy. This is why the last few milligrams can be the hardest to drop and why some people feel fine going from 100 mg to 50 mg but miserable going from 25 mg to zero.⁵

Hyperbolic tapering addresses this by making dose reductions proportionally smaller as you go lower. Instead of equal-sized steps, each reduction removes a smaller absolute amount. Some clinicians use liquid formulations diluted with water to achieve precision doses. The practical challenge is access: not all pharmacies stock liquid sertraline, and compounded preparations can be expensive depending on your insurance and location.¹² If your prescriber is unfamiliar with this approach, the growing literature on hyperbolic tapering can be a useful conversation starter.

Your Genetics Play a Role

Not everyone processes sertraline at the same speed, and the differences are genetic. The enzyme CYP2C19, produced in the liver, is the primary route by which your body breaks down sertraline. People carry different versions of the gene that codes for this enzyme, leading to dramatically different drug levels at the same dose. In a study of about 1,200 Scandinavian patients, people who were CYP2C19 poor metabolizers had sertraline blood concentrations roughly 2.7 times higher than normal metabolizers on the same dose. Their odds of exceeding the therapeutic reference range were nearly nine times higher.¹³

What does this mean for stopping? If you’re a slow metabolizer, you’ve effectively been taking a higher dose than the number on the pill suggests. That extra drug exposure may have caused deeper physiological adaptation, and the drug will clear from your system more slowly after you stop. A larger study of roughly 9,500 participants found that CYP2C19 poor metabolizers showed higher tolerability for sertraline while on it, while intermediate metabolizers reported more side effects.¹⁴ These genetic differences are worth considering if your withdrawal experience seems disproportionately severe relative to your dose and duration. Pharmacogenomic testing is available commercially and can clarify your metabolizer status, though it is not routinely ordered before prescribing.

Stopping During Pregnancy

Pregnancy adds a unique layer of complexity. Some women and their clinicians decide to stop sertraline during pregnancy out of concern for fetal exposure, while others stay on it because the risk of untreated depression is also real. A large population-based study tracked psychiatric outcomes after childbirth in women who discontinued an SSRI or SNRI during pregnancy compared with those who continued. By 90 days postpartum, rates of psychiatric hospitalization were very low in both groups (under 1%). The discontinued group had a slightly higher hazard rate for hospitalization in the first 90 days, but this evened out and actually reversed by 18 months. Psychiatric outpatient visits were significantly lower in the discontinued group at both time points. Crucially, no association with self-harm or suicide was found in either group.¹⁵

This doesn’t mean every pregnant person should stop their antidepressant. The study captured an overall population trend, and individual risk depends heavily on the severity of the underlying condition. But the data suggest that for many women, stopping an SSRI during pregnancy does not lead to dramatically worse psychiatric outcomes after delivery, which can be reassuring for those weighing the decision with their doctor.

Therapy as a Safety Net During Tapering

One of the most consistent findings in the discontinuation literature is that structured psychological therapy during the taper period significantly improves outcomes. A systematic review found that people who received cognitive behavioral therapy alongside a gradual dose reduction had relapse rates of roughly 15 to 25% over two years, compared with 35 to 80% for people who tapered with standard clinical management alone. Mindfulness-based cognitive therapy showed a similar protective effect, producing relapse rates comparable to staying on the antidepressant indefinitely.¹⁶ A separate systematic review estimated that offering CBT during tapering allowed about 26% more patients to become drug-free without relapsing, compared with tapering in routine care.¹⁷

The practical catch is access. CBT and mindfulness-based programs are resource-intensive, requiring trained therapists and multiple sessions over weeks or months. If formal therapy is out of reach, even a structured self-help program or regular check-ins with a clinician during the tapering period can provide a framework for managing the emotional turbulence that often accompanies discontinuation.

Children and Adolescents

Sertraline is one of the few SSRIs with formal approval for use in children and adolescents, primarily for obsessive-compulsive disorder. When the time comes to stop, the general principles of gradual tapering apply, but the evidence base is thinner. A systematic review of antidepressant deprescribing in young people found that withdrawal symptoms in this population overlap with those seen in adults: irritability, anxiety, nausea, headaches, dizziness, and sleep disruption. The review noted that withdrawal risk is tied to the specific drug’s pharmacokinetics, meaning that the same half-life and transporter-occupancy considerations that matter in adults apply in younger patients too.²

What makes discontinuation trickier in young people is that they may have a harder time articulating what they’re feeling. A teenager might not recognize brain zaps or describe them in a way that a parent or clinician recognizes. Irritability and mood changes during withdrawal can also be difficult to separate from normal adolescent behavior. Close monitoring during the taper, with explicit conversations about what withdrawal symptoms to watch for, helps both the young person and their family distinguish expected discomfort from something that needs clinical attention.

1
PubMed Central. The lived experience of withdrawal from Selective Serotonin Reuptake Inhibitor (SSRI) antidepressants: A qualitative interview study
2
PubMed Central. Deprescribing Antidepressants in Children and Adolescents: A Systematic Review of Discontinuation Approaches, Cross-Titration, and Withdrawal Symptoms
3
PubMed. Brain Zaps: An Underappreciated Symptom of Antidepressant Discontinuation
4
PubMed Central. Do withdrawal symptoms predict depression relapse after antidepressant cessation?
5
PubMed Central. The relationship between dose and serotonin transporter occupancy of antidepressants-a systematic review
6
PubMed Central. Estimating Risk of Antidepressant Withdrawal from a Review of Published Data
7
PubMed. Antidepressants withdrawal effects and duration of use: a survey of patients enrolled in primary care psychotherapy services
8
PubMed Central. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal
9
Molecular Psychiatry. The relationship between dose and serotonin transporter occupancy of antidepressants—a systematic review
10
PubMed Central. Stopping antidepressants: when and how
11
PubMed Central. Take-Home Messages
12
PubMed Central. Deprescribing SSRIs and Mirtazapine: Hyperbolic Tapering Techniques
13
PubMed Central. Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients
14
The Pharmacogenomics Journal. Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study
15
JAMA Network Open. Postpartum Psychiatric Outcomes and Sick Leave After Discloser Discontinuing SSRI or SNRI in Pregnancy
16
PubMed Central. Managing Antidepressant Discontinuation: A Systematic Review
17
medRxiv. Interventions to help patients withdraw from depression drugs: systematic review